The intra-abdominal infection (IAI) indicates inflammation of a single organ in the entire intra-abdominal area or peritonitis (inflammation of the abdominal lining). Major IAIs include intra-abdominal abscess, appendicitis, diverticulitis, diarrhea, food poisoning, and infection by Helicobacter pylori. Diarrhea, abdominal pain, nausea, and fever are common symptoms of IAI. It is believed that inflammation of intra-abdominal organs is caused by pathogenic microorganisms. Intra-abdominal infections are predominantly polymicrobial in nature. These infections are primarily caused by H. pylori, Streptococcus, Enterococcus, E. coli, Pseudomonas, or Klebsiella. The intra-abdominal infection can be diagnosed through numerous diagnostic tests such as blood test, computed tomography, ultrasound, and X-ray of the abdominal region. A wide range of antibiotics are administered for the treatment of intra-abdominal infection.
According to recent studies conducted, the incidence rate of intra-abdominal infections in the U.S. is estimated to be nearly 3.5 million cases per year. It is the second most leading cause of death in intrinsic care units at health care facilities such as hospitals. In 2017, Ann Surg documented that 100 out of 100,000 persons are affected by appendicitis in North America, whereas 105–151 out of 100,000 new cases of appendicitis are reported in Europe. The number of reported cases of appendicitis in countries of Asia is higher. Another journal ‘Gastroenterology’ has estimated that 4.4 billion cases of Helicobacter pylori are reported worldwide, wherein South America and Africa exhibit higher prevalence (almost 80%–90%). A joint study performed by the U.S. and Canada in 2011 stated that the U.S., Europe, and Australia showed higher prevalence of divertciluis although geographical variance is immense.
The global intra-abdominal infections market can be segmented based on disease indication, drug class, distribution channel, and region. Based on disease indication, the market has been classified into intra-abdominal abscess, appendicitis, diverticulitis, diarrhea, food poisoning, and infection by Helicobacter pylori. Based on drug class, the global intra-abdominal infection market has been divided into chloramphenicol, beta lactums, quinolones, aminoglycosides, and others. All these antibiotics are proved to be effective in treating intra-abdominal infections. Based on distribution channel, the market has been segmented into hospital pharmacies, drug stores, retail pharmacies, and e-commerce.
Increasing demand for quick and accurate non-surgical treatments and growing incidence of infectious and chronic diseases are major factors that boost the IAI market. Prevalence of diseases such as abscess, appendicitis, diverticulitis, and infection by Helicobacter pylori is of high concern for numerous developed and developing countries. Increasing awareness regarding the treatment procedure and rising health care expenditure are expected to be key factors responsible for growth of the global intra-abdominal infections market. A majority of these diseases have high prevalence in developing economies. Thus, the rise in demand for cost-effective and efficient treatment is expected to drive the global intra-abdominal infections market during the forecast period. According to the U.S. National Library of Medicine, most of the studies are funded by non-industrial organizations and performed by European organizations. For instance, Allecra Therapeutics, a Germany-based company, has been performing a study on cefepime, an antibiotic against intra-abdominal infections. It is expected to complete its phase 2 by the end of 2017. The approval of Zavicefta from AstraZeneca for Europe although commercialization rights are held by Pfizer (Allergen in the U.S. and Canada) and development of antibiotics by the University of Southampton as a replacement for surgery for appendicitis.
Geographically, the global intra-abdominal infections market has been classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North American is projected to lead the global intra-abdominal infections market during the forecast period. Dominance of North America is largely attributable due to significant rise in the number of reported cases, awareness about treatment, adequate availability of antibiotics, and increasing drug research and development activities. On the other hand, the Asia Pacific region witnesses high prevalence of IAI, rapidly growing pharmaceutical industry, and increase in public–private partnerships to promote research at academic levels, and awareness about antibiotic therapy for IAI. The market in the region is expected to register the maximum growth rate during the forecast period. Latin America and Middle East & Africa are anticipated to provide lucrative growth opportunities to the intra-abdominal infections market during the forecast period, due to developing health care infrastructure and increasing per capita expenditure led by emerging middle class in these regions.
Major players operating in the global intra-abdominal infections market are AstraZeneca Plc., Merck & Co., Inc., Pfizer, AtoxBio, Dainippon Sumitomo Pharma, Bayer Healthcare Pharmaceutical Inc., and Bristol Myers Squibb.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.